Who We Serve

Valuation and reporting solutions for life science companies

Life science organizations continually seek to create short- and long-term value through innovation and market expansion. They operate in a highly regulated environment with the potential for rapid changes in the company value, making timely and accurate valuations essential.

Proven experience

DiFilippo Corporate Finance Group has served hundreds of life sciences organizations, from development stage through regulatory approval and from seed stage to IPO or M&A, in the following industry segments:

  • Biotechnology, including lead-generating technologies, drug delivery, and gene research and development
  • Pharmaceuticals
  • Medical devices
  • Human health therapeutics
  • Life science tools and services

Karen Roberts

In addition to being valuation experts, DCF Group really knows the life science space and has a respected reputation with many of the large auditing firms. DCF has retained continuity with employees, so at each valuation point I am working with individuals familiar with the account.

– Karen Roberts, CFO, Sojournix

Holly Whittemore

DCF has been a great partner as we’ve evolved the Nimbus LLC model. The DCF team works hard to make sure we understand the models they are using and the elements of the valuation.

– Holly Whittemore, CFO, Nimbus Therapeutics